NovellusDx Cancer Early Detection Blood Test- Clinical Trial

Completed

• Conditions: Lung Cancer

• Registration Number: NCT01883388
• Lead Sponsor: Fore Biotherapeutics

Brief Summary

NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature detection. The investigators' current clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test- discriminating between cancer patients and healthy subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-06
• Study First Submitted: 2013-06-17
• Study First Submitted QC: 2013-06-19
• Study First Posted: 2013-06-21
• Status Verified: 2014-10
• Primary Completion: 2016-12
• Last Update Submitted: 2018-03-27
• Last Update Posted: 2018-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• subjects ages 18 and above ICF obtain

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test	3.5 years	NovellusDX Cancer Early Detection test will identify participants with significant cancer fingerprint based on tumor protein secretion to the blood circulation in sick subjects.

Trial Locations

Locations (1)

Rambam MC; 🇮🇱 Haifa, Israel